Initial Public Offering

Healthcare
Initial Public Offering

Summary

Baird served as a co- manager on this offering.

About

Nivalis Therapeutics, Inc. (“Nivalis” or the “Company”) (NASDAQ: NVLS) recently completed an initial public offering of 6,325,000 shares of its common stock at a price of $14.00 per share, generating gross proceeds of $88 million. The Company intends to use the net proceeds from the offering for the continued development of the lead product, N91115 and general corporate purposes.

Nivalis is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of small molecule therapeutics for patients with cystic fibrosis. In addition to bringing innovative solutions that extend and improve the lives of people with cystic fibrosis, Nivalis plans to utilize its portfolio of proprietary S-nitrosoglutathione reductase (GSNOR) inhibitors to develop therapeutics portfolio for patients with other diseases. The Company owns exclusive rights to its lead candidate, N91115, in the United States, Europe and all other major markets, including composition of matter patent protection until at least 2031. Nivalis is headquartered in Boulder, Colorado.

For additional information about this transaction, please contact:

David Schechner +1 617-426-5424
Ryan Mausehund +1 650-858-3817
Lance Lange +1 414-765-7079
Vip Patel +1 312-609-4933
David Silver +44 207 667 8216
Healthcare
Initial Public Offering
Date
July 2015
Company
Nivalis Therapeutics, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share